Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 29.05 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
28.60 29.50 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.76 -10.39 -13.49 51
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-02-20 16:29:1329.145,8331,699.74O
2020-02-20 16:28:1229.006,3791,849.91O
2020-02-20 16:27:2729.0013,7933,999.97O
2020-02-20 16:27:2429.001,068309.72O
2020-02-20 16:22:5328.553,9511,128.01O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
20/2/2020
08:20
Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 30.50p.
Avacta Group Plc has a 4 week average price of 18p and a 12 week average price of 15.75p.
The 1 year high share price is 44.50p while the 1 year low share price is currently 15.13p.
There are currently 176,036,837 shares in issue and the average daily traded volume is 2,058,305 shares. The market capitalisation of Avacta Group Plc is £51,138,701.15.
18/2/2020
18:51
the stigologist: I observed at time of the gap in January that it looked like a 'breakaway gap'. i.e. the gap would not be filled and was simply a continuation pattern/breakout to a new higher share price plane This has been borne out so far. Now we seem to be continuing along that plane and furthermore it seems obvious from extrapolating he 50 and 200 day moving average lines that a Golden Cross is inevitable within weeks This should give more technical traders a reason to jump on board so we are set fair on multiple technical, fundamental, momentum and newsflow parameters We could see serious break higher taking us on to an accelerated higher plane and share price trajectory soon which today's little excitement is perhaps an early warning of
12/2/2020
14:10
nielsenhg: A classic of a company knowing their share price is going north,is to issue a share incentive plan.Keeps the employees incentivised to work there and in due course richer.
05/2/2020
23:25
74tom: For all the positive chat from AVCT regarding being fully funded to 2021, I remain dubious. In the last 5 months of 2019 they burned £6.8m of cash, if they do the same to the end of May then they will have £2m remaining. 31/07/19 - £6.5m cash 18/10/19 - raise £9m 31/12/19 - £8.7m cash Burn for 5 months from July - Dec 19 : £6.5m + £9m - £8.7m = £6.8m Monthly burn = £1.36m £8.7m / £1.36m = 6 months cash remaining. IMO The reason the share price is down here is because they are undercapitalised, if they had £50m in cash I think the market cap would be £300m + , the problem is the frequent placings at regular intervals. Until this fact changes (hopefully due to a significant up front payment being received) I remain dubious of much progress being achieved in the share price.
05/2/2020
10:12
toffeeman: Before we get too excited the share price has finally reached the placing price of 18 months ago which was 25p in July 2018. Remember how it was driven down for the subsequent placing.....
04/2/2020
12:49
tarlok: i agree nordic....different rules apply on aim ,MM driven..just watch a small cap stock like this and see 2 or 3 sells of say 5000 shares and see what happens to share price. ps dosent work the otherway...2 or 3 buys and MM happy to sit on ask price.
04/2/2020
10:15
x54v: The newsflow so far this year has been very positive indeed. If it continues at this rate then the share price should really take off. An exciting time ahead. Lots to look forward to. ...... 3rd Feb - Avacta and Daewoong Agreement "The potential for AffyXell's new class of cell therapies, which can be applied to a wide range of inflammatory and autoimmune diseases, is enormous." "We believe that this has the potential to create substantial value for stakeholders in the near future." Https://investegate.co.uk/avacta-group-plc--avct-/rns/avacta-and-daewoong-agreement/202002030700106520B/ 28th Jan - Successful initial proof-of-concept "These in vivo efficacy and distribution data demonstrate initial proof-of-concept for TMAC drug conjugates and represent an important milestone for the Company." "We continue to receive significant commercial interest in the TMAC concept" "This is hugely encouraging for the TMAC programme" Https://investegate.co.uk/avacta-group-plc--avct-/rns/successful-initial-proof-of-concept/202001280700130774B/ 23rd Jan - Trading Update "Revenues for the period, which include the initial milestone payment from LG Chem, have grown 100% to £5.5m from £2.76m (12 months ended 31 July 2018) and are ahead of market expectations." "Importantly revenues from the Affimer® diagnostics business have grown by 130% as more customer evaluations of the Affimer® platform are underway." "The Group's order intake and sales pipeline into 2020 are the strongest to date." "The cash position at 31 December 2019 was £8.7m (31 July 2018: £5.2m), also ahead of market forecasts" "I am therefore looking ahead with confidence and believe 2020 will be an exciting year of further progress." Https://investegate.co.uk/avacta-group-plc--avct-/rns/trading-update/202001230700046434A/ 8th Jan - Avacta and Daewoong Establish Joint Venture "Cell and gene therapies are attracting intense clinical and commercial interest. We are very excited to establish this joint venture with Daewoong, one of the top pharmaceutical companies in Korea, to develop the Affimer platform in this important therapeutic area. Our vision is to combine our platforms to create the next generation of cell therapies, for which the potential is huge. " Https://investegate.co.uk/avacta-group-plc--avct-/rns/avacta-and-daewoong-establish-joint-venture/202001080700051128Z/
30/1/2020
16:48
money multipier: TheSaint, where does the $5.5M figure come from? There will be milestones on successful pre-clinical from LG Chem, but I don't know how much and when. The potential $50M would only come after successful phase 1, and assuming no further slippage will be year end. Don't get me wrong, I'm more optimistic about the potential here than I ever have been, but I been here a while and the dilution caused by the need for cash has hurt existing holders as the company did little keep the share price at a value that reflected the potential, which is why the share price dived as the cash ran out last year. I hope the lesson has been learnt and cash doesn't become a problem in future.
26/1/2020
11:57
tromso1: "Next week #AVCT will become my largest holding. Will share notes I’m completing, later next week. Neer seen such share price appreciation potential in a Co over a 2 year period. 2 successful Phase I trials, validating AVCT’s 2 tech platforms in humans, offers unicorn potential." Https://twitter.com/MylesMcNulty/status/1221148292018593794
16/1/2020
15:45
the stigologist: That's a great word. Love it. Can't wait for AVCT to become a supercentarian share price
22/10/2019
22:38
escapetohome: Many companies : (A)make it clear they need to raise cash (b) manage to sign several deals which they would have expected to have increased the share price (c) communicated extensively with the market via RNSs and presentations (d) raise the cash. And their share price rises as planned. Avactas falls. WHY.???????
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200221 07:22:29